tradingkey.logo

Tempus AI Inc reports results for the quarter ended March 31 - Earnings Summary

ReutersMay 6, 2025 9:01 PM
  • Tempus AI Inc TEM.OQ reported a quarterly adjusted loss of 24 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of $-1.47. The mean expectation of twelve analysts for the quarter was for a loss of 27 cents per share. Wall Street expected results to range from -38 cents to -20 cents per share.

  • Revenue rose 75.4% to $255.74 million from a year ago; analysts expected $248.13 million.

  • Tempus AI Inc's reported EPS for the quarter was a loss of 40 cents​.

  • The company reported a quarterly loss of $68.04 million.

  • Tempus AI Inc shares had risen by 12.1% this quarter and gained 60.2% so far this year.

FORECAST CHANGES

  • The mean earnings estimate of analysts had fallen by about 4.8% in the last three months.​

  • In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," 6 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

  • Wall Street's median 12-month price target for Tempus AI Inc is $62.00

This summary was machine generated from LSEG data May 6 at 09:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING

ESTIMATE

ACTUAL

BEAT, MET, MISSED

Mar. 31 2025

-0.27

-0.24

Beat

Dec. 31 2024

-0.20

-0.18

Beat

Sep. 30 2024

-0.31

-0.25

Beat

Jun. 30 2024

-1.30

-0.63

Beat

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI